Melasma treatment after menopause should start with a diagnosis, not with the strongest lightening cream in the search result.
The evidence supports a stepwise plan: in 20 randomized studies with 2,125 participants, triple-combination cream lightened melasma better than hydroquinone alone, but the same Cochrane review judged the overall study quality generally poor. [1] In a separate 68-person randomized trial, visible-light protection added to UV sunscreen improved MASI scores 15% more than UV-only sunscreen when both groups used 4% hydroquinone. [6]
That combination is the practical answer: confirm the pigment pattern, protect against light every day, then choose the treatment category that fits the person instead of chasing one permanent cure.
Start with diagnosis before pigment treatment
New pigmentation after menopause is common enough to search, but not every brown patch is melasma. Melasma is usually symmetric and gray-brown or brown. Light exposure often makes it worse. A changing, irregular, bleeding, painful, fast-growing, or unusual spot should be checked before pigment treatment, because lightening cream should not hide a lesion that needs examination. [9]
The diagnosis step separates melasma from lentigines, post-inflammatory hyperpigmentation, medication-related pigment, actinic damage, seborrheic keratoses, and lesions that need dermoscopy or biopsy. That distinction matters because the safest treatment for melasma may be the wrong response to a changing spot.
Why menopause and hormones enter the conversation
Melasma is influenced by ultraviolet exposure, visible light, genetics, and hormones. Pregnancy and oral contraceptives have long been linked with melasma. The evidence for hormone therapy after menopause is much thinner.
A 2026 review of hormone replacement therapy and melasma found limited evidence, mostly case reports. High-dose oral estrogen-only hormone replacement therapy had the strongest documented association, especially in women with Fitzpatrick skin types III to VI and forearm melasma. Case reports also exist for combined oral and transdermal hormone replacement therapy. Topical and vaginal estrogen had minimal evidence for a link. [3] Earlier case-series evidence also described forearm melasma in older patients, especially postmenopausal women using supplementary estrogen. [4]
That means a postmenopausal woman with new melasma should not assume hormone replacement therapy is the cause. But if pigmentation appears or worsens after hormone changes, it is reasonable to tell the treating clinician and tighten photoprotection.
What treatment fits which melasma situation?
Photoprotection is the base layer. Without daily sunscreen and visible-light protection when relevant, melasma treatment is more likely to relapse.
| Situation | Better first category | Why it fits | Caution |
|---|---|---|---|
| New or changing spot | Dermatology diagnosis | Melasma treatment should not hide a lesion that needs evaluation. | Bleeding, pain, rapid growth, asymmetry, or irregular color needs exam first. |
| Confirmed symmetric melasma | Photoprotection plus topical plan | Sunscreen and visible-light protection support nearly every treatment. | Relapse is common if light, heat, irritation, or hormones keep driving pigment. |
| Moderate-to-severe facial melasma | Hydroquinone or triple-combination discussion | Cochrane found triple-combination cream more effective than hydroquinone alone (relative risk 1.58). [1] | Needs duration, irritation, steroid, pregnancy-potential, and ochronosis boundaries. |
| Acne, rosacea overlap, or hydroquinone concerns | Azelaic acid discussion | Six randomized controlled trials with 673 patients found a MASI advantage versus hydroquinone. [2] | Long-term comparative data are still limited. |
| Refractory melasma | Procedure discussion after topicals | Laser/light plus topicals improved scores at 8-16 weeks in a 2026 review. [5] | Adverse-event odds were higher, mainly redness and post-inflammatory hyperpigmentation. |
| Considering oral tranexamic acid | Off-label clot-risk review | A 2024 meta-analysis of 22 studies and 1,280 patients found TXA reduced melasma severity. [7] | U.S. tablet labeling is not for melasma and includes thromboembolic contraindications. [8] |
This is why "best melasma treatment" has no one-line universal answer. The best fit changes with diagnosis certainty, skin type, irritation risk, pregnancy potential, hormone replacement therapy timing, clot risk, procedures, and whether daily light protection is realistic.
What the topical evidence really says
The classic high-evidence topical category is hydroquinone-containing therapy, especially triple-combination cream. Triple-combination cream combines hydroquinone, tretinoin, and fluocinolone. In the Cochrane review, it was more effective than hydroquinone alone (relative risk 1.58, 95% confidence interval 1.26-1.97), tretinoin plus hydroquinone (relative risk 2.75, 95% confidence interval 1.59-4.74), tretinoin plus fluocinolone (relative risk 14.00, 95% confidence interval 4.43-44.25), and hydroquinone plus fluocinolone (relative risk 10.50, 95% confidence interval 3.85-28.60). [1]
The plain-language meaning is that combination treatment has stronger lightening evidence than single-agent hydroquinone in the trials Cochrane reviewed. The limitation is just as important: the review included 20 studies across 23 treatments, could not pool the data because treatments were heterogeneous, and judged overall quality generally poor. [1]
TRI-LUMA is the label-level example of this class. Its current DailyMed label describes a 0.01% fluocinolone acetonide, 4% hydroquinone, and 0.05% tretinoin cream for short-term treatment of moderate-to-severe facial melasma with sun-avoidance measures, including sunscreen. The label says to apply a thin film once daily at least 30 minutes before bedtime, discontinue when control is achieved, use SPF 30 during the day, and avoid sunlight exposure. [6]
The same label shows why this is not a casual brightening product. In controlled 8-week trials of 161 subjects, 102 (63%) had at least one treatment-related adverse event. Reported treatment-related events included erythema in 41%, desquamation in 38%, burning in 18%, dryness in 14%, pruritus in 11%, and acne in 5%. The label also warns about hypersensitivity and hydroquinone-associated exogenous ochronosis, a gradual blue-black darkening that should prompt discontinuation. [6]
Azelaic acid is the other topical category to discuss seriously. A 2023 meta-analysis of six randomized studies with 673 patients found azelaic acid had greater MASI reduction than hydroquinone (MD -1.23, 95% confidence interval -2.05 to -0.40, P = 0.004), while objective response, pigmentation reduction, and adverse events were not clearly different. [2]
That makes azelaic acid a reasonable discussion for patients who need a different irritation or safety profile, especially when acne or rosacea overlap is part of the picture. It does not make azelaic acid a guaranteed substitute for every hydroquinone plan.
Photoprotection is treatment, not background advice
Melasma is one of the places where sunscreen advice is part of the active treatment, not a polite add-on. UV protection matters, and visible light can matter too, especially in darker skin types and persistent pigment.
In a double-blind randomized trial, 68 patients with melasma were assigned to UV-visible-light sunscreen with iron oxide or UV-only broad-spectrum sunscreen for 8 weeks. Both groups used 4% hydroquinone. Sixty-one patients completed the study. The UV-visible-light group had 15% greater improvement in MASI, 28% greater improvement in colorimetry, and 4% greater improvement in melanin assessment than the UV-only group. [6]
The useful takeaway is narrow and practical: tinted visible-light protection can strengthen a real melasma plan, but the trial did not test sunscreen as a stand-alone cure. It tested better photoprotection while both groups used hydroquinone.
Where lasers, peels, and procedures fit
Procedures are not the first step for every patient. A 2026 review of 11 randomized trials with 461 people found that laser or light-based therapy plus topical treatment showed no significant benefit at 4 weeks, but statistically significant improvement at 8, 12, and 16 weeks. The pooled effect at those timepoints was SMD -0.55 (95% confidence interval -0.74 to -0.36; P < 0.00001). [5]
The safety signal is the reason to slow down. The same review found higher adverse-event risk in combination laser/light groups (odds ratio 8.96, 95% confidence interval 3.71-21.64), mainly erythema and post-inflammatory hyperpigmentation. Evidence certainty was moderate for efficacy and very low for safety. [5]
That tradeoff is especially important for darker skin types and for anyone prone to post-inflammatory hyperpigmentation. The right question is not "which laser is strongest?" It is "what is the diagnosis, skin type, relapse risk, and safest step-by-step plan?"
When oral tranexamic acid belongs in the conversation
Tranexamic acid appears in melasma searches because trials and reviews show pigment improvement. A 2024 meta-analysis included 22 studies with 1,280 patients, with oral, topical, and injected routes and treatment durations from 8 weeks to nearly 2 years. It found significant reductions in MASI, modified MASI, melanin index, and hemi-MASI scores; oral tranexamic acid showed the largest MASI decrease, followed by injections and topical use. Reported adverse effects included gastrointestinal discomfort, skin irritation, and menstrual irregularities. The authors emphasized heterogeneity and the need for standard protocols. [7]
The U.S. safety frame is stricter than the search-result frame. DailyMed labeling for tranexamic acid tablets is for cyclic heavy menstrual bleeding in females of reproductive potential, not for melasma, and the patient information says it is not for women who have already gone through menopause. The label contraindicates use with combined hormonal contraception, active thromboembolic disease, a history or intrinsic risk of thrombosis or thromboembolism, retinal vein or artery occlusion history, and hypersensitivity. It also warns about venous and arterial thrombosis, retinal occlusion, visual or ocular symptoms, and severe allergic reactions. [8]
For a postmenopausal woman, that means oral tranexamic acid should be treated as an off-label dermatology discussion with clot-risk, hormone-use, smoking, surgery, migraine, eye-symptom, kidney, and medication screening. It should not be presented as a casual brightening pill.
Red flags and avoid-first situations
| Finding or history | Why it changes the plan | Better next step |
|---|---|---|
| Changing, bleeding, painful, irregular, fast-growing, or unusual lesion | Pigment treatment can delay diagnosis of a concerning skin lesion. | Dermatology exam before lightening treatment. [9] |
| Unconfirmed diagnosis | Lentigines, post-inflammatory pigment, medication pigment, and actinic damage may need different care. | Diagnosis, photos, and trigger review first. |
| Recent peel, burn, irritation, rash, or barrier damage | Irritation can worsen post-inflammatory hyperpigmentation. | Calm the skin before adding stronger actives. |
| Inconsistent sunscreen use | Most melasma treatments relapse or underperform without light control. | Build daily UV and visible-light protection first. |
| Prior pigment worsening after procedures | Laser/light and peels can cause erythema or post-inflammatory hyperpigmentation. | Procedure caution, lower-risk topicals, or specialist care. [5] |
| Hydroquinone darkening, blue-black color, or allergy symptoms | TRI-LUMA labeling warns about exogenous ochronosis and hypersensitivity. | Stop and contact the clinician. [6] |
| Clot history, stroke history, retinal vessel history, thrombophilia, smoking with hormone exposure, or combined hormonal contraception | Tranexamic acid labeling includes thromboembolic contraindications and warnings. | Avoid casual TXA use; clinician risk review only. [8] |
| Visual or ocular symptoms while using tranexamic acid | Labeling warns about retinal venous and arterial occlusion. | Stop and urgent clinician/eye evaluation. [8] |
A practical midlife pigmentation plan
A structured skin assessment usually starts with:
- Confirming the diagnosis and deciding whether any spot needs dermoscopy, biopsy, or a different diagnosis.
- Reviewing triggers: UV, visible light, heat, prior procedures, acne, irritation, hormone therapy, medications, pregnancy potential, and family history.
- Building daily photoprotection that the patient can actually maintain, including visible-light protection when relevant.
- Choosing a topical category: hydroquinone-containing therapy, azelaic acid, retinoid-containing therapy, or another plan based on skin tolerance and contraindications.
- Defining irritation stop rules and relapse expectations before treatment starts.
- Reserving lasers, peels, microneedling, or oral tranexamic acid for selected cases after risk review.
If pigmentation changed around a new hormone therapy, the answer is not to stop medication from an article. It is to bring the timeline into the hormone therapy risk-benefit review and the skin plan at the same time.
How treatment choice changes by situation
Photoprotection fits everyone with suspected melasma because UV and visible light can maintain pigment. Tinted mineral sunscreen with iron oxides may be especially relevant when visible light worsens pigment.
Hydroquinone-containing or triple-combination therapy may fit confirmed melasma when a clinician can manage irritation, steroid exposure, pregnancy potential, duration, and relapse. Azelaic acid may fit patients who need a different topical risk profile or who also have acne or rosacea overlap.
Procedures should be avoided as a casual first step when the diagnosis is uncertain, skin is easily inflamed, or post-inflammatory hyperpigmentation risk is high. Lasers, peels, and microneedling need a clinician who can explain relapse risk, skin-type risk, and stop rules.
Oral tranexamic acid may fit only a carefully selected off-label discussion after diagnosis, photoprotection, topical options, and clot-risk screening. It should be avoided when label-level thromboembolic contraindications or visual-symptom concerns are present.
Bottom line
Melasma after menopause is best treated as a chronic pigment condition with diagnosis, daily light protection, relapse planning, and treatment-specific safety checks.
The highest-leverage decision is not one permanent cure. It is matching the category: photoprotection for everyone, topicals for confirmed melasma when irritation and duration can be managed, procedures only with skin-type and PIH risk planning, and oral tranexamic acid only after careful off-label clot-risk screening.
What to ask your clinician
- Is this definitely melasma, or could it be lentigines, post-inflammatory hyperpigmentation, medication pigment, or a lesion that needs examination?
- Which photoprotection plan should I use daily, including visible-light protection when relevant?
- Is hydroquinone, triple-combination therapy, azelaic acid, retinoid, or another topical option the best fit for my skin type and irritation risk?
- Did hormone therapy, medication changes, heat, sun exposure, or procedures change the timing of my pigment?
- If we use hydroquinone or a triple-combination cream, what is the exact duration, stop rule, maintenance plan, and side-effect plan?
- Would oral tranexamic acid be off label in my case, and do my clot history, hormone use, smoking, migraine, kidney function, eye symptoms, surgery plans, or medications make it a poor fit?
- What would make a laser, light device, peel, or microneedling too risky for me?
Related reading:
- Hydroquinone and TRI-LUMA: Melasma Safety After Menopause.
- Tinted Sunscreen for Melasma After Menopause.
- Tranexamic Acid for Melasma After Menopause: Clot Screening.
- Niacinamide After Menopause.
References
[1] Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010;2010(7):CD003583. doi:10.1002/14651858.cd003583.pub2 https://pubmed.ncbi.nlm.nih.gov/20614435/
[2] Albzea W, AlRashidi R, Alkandari D, et al. Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2023;15(7):e41796. doi:10.7759/cureus.41796 https://pubmed.ncbi.nlm.nih.gov/37457606/
[3] Abdeen S, Shao E, Lim D. Does Hormone Replacement Therapy Influence Melasma Development? A Review of the Evidence and Management Guidelines. Dermatol Surg. 2026. doi:10.1097/dss.0000000000005032 https://pubmed.ncbi.nlm.nih.gov/41603615/
[4] O'Brien TJ, Dyall-Smith D, Hall AP. Melasma of the forearms. Australas J Dermatol. 1997;38(1):35-7. doi:10.1111/j.1440-0960.1997.tb01097.x https://pubmed.ncbi.nlm.nih.gov/9046652/
[5] Fithria RF, Supranoto YTN, Liu Z, Peng J. Laser and light-based therapies combined with topical agents for melasma: A systematic review and meta-analysis. Medicine (Baltimore). 2026;105(2):e46579. doi:10.1097/md.0000000000046579 https://pubmed.ncbi.nlm.nih.gov/41517728/
[6] DailyMed. TRI-LUMA fluocinolone acetonide, hydroquinone, and tretinoin cream prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a35fa709-5eb5-4429-b38f-f1e0019bf0ee
[7] Calacattawi R, Alshahrani M, Aleid M, et al. Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials. J Dermatolog Treat. 2024;35(1):2361106. doi:10.1080/09546634.2024.2361106 https://pubmed.ncbi.nlm.nih.gov/38843906/
[8] DailyMed. Tranexamic acid tablet prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5a52dad-e328-48f2-9182-4df46f5572ef
[9] American Academy of Dermatology Association. Melanoma: the most serious form of skin cancer. https://www.aad.org/media/stats-melanoma